MIDDLE EAST AND ASIA PACIFIC CELL AND GENE THERAPY MARKET ANALYSIS

Middle East and Asia Pacific Cell and Gene Therapy Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), by Technology (Lentiviral Vector, Plasmid DNA, and AAV), and by Region (Middle East and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Mar 2022
Code : CMI4981
Pages :425
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Key Players

Major players operating in the Middle East and Asia Pacific cell and gene therapy market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bluebird Bio, Inc. (Celgene Corporation), Gene biotherapeutics, Sibiono GeneTech Co. Ltd., Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Biogen INC., Organogenesis, Inc., JCR Pharmaceuticals Co. Ltd, uniQure N.V., WuxiAppTec, Lonza, and Immuneel Therapeutics Pvt Ltd.